Login to Your Account

Celyad, Ono ink $312M preclinical, T-cell immunotherapy pact

By Nuala Moran
Staff Writer

Monday, July 11, 2016

LONDON – Celyad SA bounced back from the phase III failure of its C-Cure stem cell therapy in congestive heart failure to seal a $311.5 million plus royalties deal with Japanese pharma Ono Pharmaceutical Co Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription